Evolus, Inc.

NasdaqGM:EOLS Stock Report

Market Cap: US$701.6m

Evolus Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

David Moatazedi

Chief executive officer

US$11.2m

Total compensation

CEO salary percentage6.1%
CEO tenure6.6yrs
CEO ownershipn/a
Management average tenure3.1yrs
Board average tenure6.6yrs

Recent management updates

Recent updates

Evolus, Inc. (NASDAQ:EOLS) Might Not Be As Mispriced As It Looks After Plunging 26%

Nov 13
Evolus, Inc. (NASDAQ:EOLS) Might Not Be As Mispriced As It Looks After Plunging 26%

Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?

Oct 22
Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?

Evolus Continues To Make Progress

Aug 02

Evolus, Inc. (NASDAQ:EOLS) Looks Just Right With A 32% Price Jump

Aug 02
Evolus, Inc. (NASDAQ:EOLS) Looks Just Right With A 32% Price Jump

Evolus (NASDAQ:EOLS) Is Making Moderate Use Of Debt

Jul 13
Evolus (NASDAQ:EOLS) Is Making Moderate Use Of Debt

Evolus: Chiseling Away At The Aesthetic Market

May 22

Analysts Are Updating Their Evolus, Inc. (NASDAQ:EOLS) Estimates After Its First-Quarter Results

May 10
Analysts Are Updating Their Evolus, Inc. (NASDAQ:EOLS) Estimates After Its First-Quarter Results

Evolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028

Mar 20

The Evolus, Inc. (NASDAQ:EOLS) Full-Year Results Are Out And Analysts Have Published New Forecasts

Mar 10
The Evolus, Inc. (NASDAQ:EOLS) Full-Year Results Are Out And Analysts Have Published New Forecasts

Evolus, Inc. (NASDAQ:EOLS) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Jan 18
Evolus, Inc. (NASDAQ:EOLS) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Evolus, Inc.'s (NASDAQ:EOLS) Shares Climb 27% But Its Business Is Yet to Catch Up

Jan 18
Evolus, Inc.'s (NASDAQ:EOLS) Shares Climb 27% But Its Business Is Yet to Catch Up

Would Evolus (NASDAQ:EOLS) Be Better Off With Less Debt?

Jun 16
Would Evolus (NASDAQ:EOLS) Be Better Off With Less Debt?

Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?

Nov 06
Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?

Evolus concludes certain royalty payments related to settlement of IP rights dispute

Sep 21

Evolus: Turning That Frown Upside Down

Sep 11

Evolus appoints Experian's exec as CFO

Aug 30

Is Evolus (NASDAQ:EOLS) Using Too Much Debt?

Aug 04
Is Evolus (NASDAQ:EOLS) Using Too Much Debt?

Evolus Q2 2022 Earnings Preview

Aug 01

Is Evolus (NASDAQ:EOLS) Using Debt Sensibly?

Mar 21
Is Evolus (NASDAQ:EOLS) Using Debt Sensibly?

CEO Compensation Analysis

How has David Moatazedi's remuneration changed compared to Evolus's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$55m

Jun 30 2024n/an/a

-US$53m

Mar 31 2024n/an/a

-US$60m

Dec 31 2023US$11mUS$688k

-US$62m

Sep 30 2023n/an/a

-US$63m

Jun 30 2023n/an/a

-US$66m

Mar 31 2023n/an/a

-US$72m

Dec 31 2022US$4mUS$597k

-US$74m

Sep 30 2022n/an/a

-US$79m

Jun 30 2022n/an/a

-US$79m

Mar 31 2022n/an/a

-US$71m

Dec 31 2021US$4mUS$572k

-US$47m

Sep 30 2021n/an/a

-US$139m

Jun 30 2021n/an/a

-US$131m

Mar 31 2021n/an/a

-US$137m

Dec 31 2020US$3mUS$527k

-US$163m

Sep 30 2020n/an/a

-US$67m

Jun 30 2020n/an/a

-US$82m

Mar 31 2020n/an/a

-US$99m

Dec 31 2019US$2mUS$550k

-US$90m

Sep 30 2019n/an/a

-US$88m

Jun 30 2019n/an/a

-US$73m

Mar 31 2019n/an/a

-US$52m

Dec 31 2018US$6mUS$362k

-US$47m

Compensation vs Market: David's total compensation ($USD11.24M) is above average for companies of similar size in the US market ($USD3.21M).

Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.

CEO

David Moatazedi (46 yo)

6.6yrs

Tenure

US$11,240,447

Compensation

Mr. David Moatazedi is Independent Director at Biomerica Inc. from December 07, 2022. He has been the President, Chief Executive Officer and Director of Evolus, Inc. since joining it on May 6, 2018. Mr. Mo...

Leadership Team

NamePositionTenureCompensationOwnership
David Moatazedi
President6.6yrsUS$11.24mno data
Sandra Beaver
Chief Financial Officer2.3yrsUS$2.46m0.052%
$ 363.3k
Rui Avelar
Chief Medical Officer and Head of Research & Development10.9yrsUS$2.93m0.31%
$ 2.2m
Nareg Sagherian
Head of Global Investor Relations & Corporate Communicationsless than a yearno datano data
Jeffrey Plumer
General Counselno datano datano data
Kurt Knab
Vice President of Sales6.2yrsno datano data
Tomoko Yamagishi-Dressler
Chief Marketing Officer1.3yrsno data0.016%
$ 113.1k
Jessica Novak
Senior Vice President of Human Resources3.1yrsno datano data

3.1yrs

Average Tenure

46yo

Average Age

Experienced Management: EOLS's management team is considered experienced (3.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
David Moatazedi
President6.6yrsUS$11.24mno data
David Gill
Independent Director6.8yrsUS$256.03k0.043%
$ 304.7k
Simone Blank
Director6.9yrsUS$235.03k0.86%
$ 6.1m
Albert White
Independent Directorless than a yearno datano data
Vikram Malik
Chairman of the Board6.9yrsUS$271.03k0.37%
$ 2.6m
Karah Parschauer
Independent Director5.4yrsUS$249.03k0.049%
$ 346.2k
Brady Stewart
Independent Director2.9yrsUS$222.03k0.071%
$ 496.4k

6.6yrs

Average Tenure

54yo

Average Age

Experienced Board: EOLS's board of directors are considered experienced (6.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 23:31
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Evolus, Inc. is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Balaji PrasadBarclays
Balaji PrasadBarclays
Navann Ty DietschiBNP Paribas Exane